RESOF L SOFOSBUVIR AND LEDIPASVIR 400MG TABLETS

Get a Price/Quote

RESOF L SOFOSBUVIR AND LEDIPASVIR 400MG TABLETS Specification

Dosage Form
Tablet

Pacakaging (Quantity Per Box)
1 Bottle/Box (28 Tablets)

Origin of Medicine
India

Indication
Treatment of chronic hepatitis C genotype 1, 4, 5, or 6 infection

Salt Composition
Sofosbuvir 400mg + Ledipasvir 90mg

Drug Type
Allopathic

Ingredients
Sofosbuvir 400mg and Ledipasvir 90mg

Physical Form
Tablets

Function
Antiviral (Hepatitis C Virus Inhibitor)

Recommended For
Chronic Hepatitis C Infection

Dosage
As prescribed by physician

Dosage Guidelines
Oral, once daily or as directed by healthcare professional

Suitable For
Adults

Quantity
28 Tablets

Storage Instructions
Store below 30C, protect from moisture and light

Prescription Required
Yes

Packaging Type
Plastic Bottle in Carton Box

Registration Status
Registered Rx

Color
Yellow, film-coated

Expiry
24 months from manufacturing date

Marketed By
Dr. Reddy's Laboratories Ltd.

Route of Administration
Oral

Brand Name
RESOF L

Product Status
Prescription

Side Effects
Fatigue, headache, nausea (consult physician for full list)

MRP
As per market

Treatment Duration
Usually 12 weeks or as directed

RESOF L SOFOSBUVIR AND LEDIPASVIR 400MG TABLETS Trade Information

Packaging Details
PACK OF 28 TABLETS

About RESOF L SOFOSBUVIR AND LEDIPASVIR 400MG TABLETS

Resof L - Sofosbuvir 400mg And Ledipasvir 90mg

Specifications:

Brand Name : Resof L
Content : Sofosbuvir and Ledipasvir
Strength: Sofosbuvir 400 mg & Ledipasvir 90 mg
Packing: 1X28 Tablets
Type: Tablets
Uses: Hepatitis C
Manufactured By : Dr. Reddys

Note : Resof L Is A Prescription Drug And Should Be Used Under Proper Medical Guidance And Advice. Do Not Share The Medicine With Others, Since They May Be Suffering From A Problem That Is Not Effectively Treated By This Drug............

Comprehensive Hepatitis C Treatment

RESOF L combines Sofosbuvir and Ledipasvir, two direct-acting antivirals effective against specific hepatitis C genotypes, offering a simplified, once-daily oral dose regimen. Its potent formulation aids in eliminating the virus from the body, reducing the risk of liver complications.

Convenient Dosing and Packaging

Packaged in a durable plastic bottle and housed in a carton box, each unit contains 28 tabletsensuring a 4-week supply. The film-coated, yellow tablets are taken orally, usually once daily and always as prescribed.

Safe Usage and Storage

RESOF L is intended for adult use under medical supervision, requiring a prescription. It must be stored below 30C, protected from excessive moisture and light, ensuring product stability over its 24-month shelf life.

FAQs of RESOF L SOFOSBUVIR AND LEDIPASVIR 400MG TABLETS:

Q: How should RESOF L tablets be used for hepatitis C treatment?

A: RESOF L is taken orally, once daily, as prescribed by your physician, usually for a 12-week course. Follow the exact dosage and duration recommended by your healthcare provider for optimal results.

Q: What are the benefits of using RESOF L for hepatitis C patients?

A: RESOF L effectively inhibits hepatitis C virus replication, greatly increasing the chances of viral clearance for genotypes 1, 4, 5, and 6, potentially improving liver health and preventing disease progression.

Q: When will you start seeing results from RESOF L therapy?

A: Many patients observe a significant reduction in hepatitis C viral load within the first few weeks of therapy. Full benefits typically require completing the prescribed course, after which your doctor will assess your viral status.

Q: Where should RESOF L tablets be stored?

A: Store RESOF L below 30C in its original packaging, protected from light and moisture. These conditions help maintain its effectiveness and shelf life up to 24 months from the manufacturing date.

Q: What are the possible side effects of RESOF L and what should I do if they occur?

A: Common side effects include fatigue, headache, and nausea. If you experience severe or unusual symptoms, contact your physician promptly for further evaluation and guidance.